Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
A phase 2 trial of Oregovomab, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.
Overview
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05605535 by CanariaBio Inc., with 88 participants planned, started 2023-02-07 and due to reach its primary completion in 2026-10-15. Interventions recorded: Oregovomab, Paclitaxel, Carboplatin, Placebo. Conditions listed: Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Oregovomab, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Shares Oregovomab, Ovarian cancer.
- TrialA Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
Shares Oregovomab, Ovarian cancer.
- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialA Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialStudy of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.